

ERYTECH Pharma's Mixed General Shareholders' Meeting of 24th June 2016 voting results by resolution

Place de cotation : Euronext Paris de NYSE Euronext
Compartment : Compartiment B
Code ISIN : FR0011471135
Site web : www.erytech.com

ERYTECH PHARMA
French *Société Anonyme*
With a sharecapital of Euros 792 461,10
Head Office : 60 Avenue Rockefeller
Bâtiment Adénine
69008 LYON - FRANCE
479 560 013 RCS LYON

Number of shares composing the capital : 7 939 831 shares

Number of shares with voting right : 7 937 331 shares

Number total of voting rights : 9 664 777 voting rights

Legal *quorum* :

- For the extraordinary decisions, is 25% of the shares having the right to vote, as to know 1 984 333 shares;
- For the ordinary decisions, is 20 % of the shares having the right to vote, as to know 1 587 467 shares.

	Number of Shareholders	Number of shares	Number of voting rights
Present to the meeting	8	630 716	1 204 740
Proxies	2	90 810	180 560
Proxies to the President	8	1 174 301	2 219 103
Postal voting forms	38	2 292 730	2 293 180
Total	56	4 188 557	5 897 583

The date of the General Shareholders' Meeting, the quorum was 52,786% representing 4 188 557 shares for 56 shareholders and 5 897 583 shares with voting rights.

Results by resolution :

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
1	Approval of the financial statements for the year ended December 31, 2015	Adopted	5 896 423	99,98%	1 160	0,02%	-	0,00%	5 897 583	-
2	Approval of the consolidated financial statements for the year ended December 31, 2015	Adopted	5 896 423	99,98%	1 160	0,02%	-	0,00%	5 897 583	-
3	Allocation of net loss for the year	Adopted	5 896 423	99,98%	1 160	0,02%	-	0,00%	5 897 583	-
4	Statutory Auditors' special report on regulated agreements and commitments with related parties	Adopted	5 352 925	96,37%	201 587	3,63%	-	0,00%	5 554 512	343 071
5	Approval of commitments pursuant to Article L.225-38 of the French Commercial Code regarding the severance package of Jérôme Bailly on account of the termination of his position	Adopted	5 300 004	89,88%	596 519	10,12%	-	0,00%	5 896 523	1 060
6	Approval of commitments pursuant to Article L.225-38 of the French Commercial Code regarding the severance or change-of-duties package of Jérôme Bailly in the event of a change in control	Adopted	5 287 697	89,67%	608 826	10,33%	-	0,00%	5 896 523	1 060

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
7	Approval of commitments pursuant to Article L.225-38 of the French Commercial Code regarding the severance or change-of-duties package of Yann Godfrin in the event of a change in control	Adopted	5 348 692	96,28%	206 880	3,72%	-	0,00%	5 555 572	342 011
8	Approval of commitments pursuant to Article L.225-38 of the French Commercial Code regarding the severance or change-of-duties package of Gil Beyen in the event of a change in control	Adopted	5 288 757	89,68%	608 826	10,32%	-	0,00%	5 897 583	-
9	Setting of attendance fees allocated to the Board of Directors	Adopted	5 600 832	94,97%	296 751	5,03%	-	0,00%	5 897 583	-
10	Renewal of directors' terms of office (Gil BEYEN)	Adopted	5 726 906	97,11%	170 677	2,89%	-	0,00%	5 897 583	-
11	Renewal of directors' terms of office (Luc DOCHEZ)	Adopted	5 341 362	90,57%	556 221	9,43%	-	0,00%	5 897 583	-
12	Renewal of directors' terms of office (Philippe ARCHINARD)	Adopted	5 727 156	97,11%	170 427	2,89%	-	0,00%	5 897 583	-
13	Renewal of directors' terms of office (GALENOS)	Adopted	5 829 386	98,84%	68 197	1,16%	-	0,00%	5 897 583	-
14	Appointment of a principal joint statutory auditor	Adopted	5 897 583	100,00%	-	0,00%	-	0,00%	5 897 583	-

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
15	Appointment of an alternate joint statutory auditor	Adopted	5 829 386	98,84%	68 197	1,16%	-	0,00%	5 897 583	-
16	Authorization for the Company to buy back its own shares	Adopted	5 368 269	91,02%	529 314	8,98%	-	0,00%	5 897 583	-
17	Authorization for the Board of Directors to reduce the Company's share capital by cancelling the treasury shares held by the Company	Adopted	5 695 746	96,58%	201 837	3,42%	-	0,00%	5 897 583	-
18	Delegation of authority to the Board of Directors to issue common Company shares and marketable securities giving access to common shares to be issued by the Company immediately or in the future, with preemptive subscription rights maintained	Adopted	5 059 972	85,80%	837 611	14,20%	-	0,00%	5 897 583	-
19	Delegation of authority to the Board of Directors to issue common Company shares and marketable securities giving access to common shares to be issued by the Company immediately or in the future with shareholders' preemptive subscription rights waived in the context of a public offering	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
20	Delegation of authority to the Board of Directors to issue common Company shares and marketable securities giving access to common shares to be issued by the Company immediately or in the future, with preemptive subscription rights waived, in connection with offerings within the provisions in section II of Article L. 411-2 of the French Monetary and Financial Code	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-
21	Authorization to the Board of Directors to set the price of any issue of common Company shares or marketable securities giving access to common shares to be issued by the Company, with preemptive subscription rights waived, at an amount not to exceed 10% of share capital per year in accordance with the conditions set out by the General Shareholders' Meeting	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-
22	Authorization to the Board of Directors to increase the number of securities to be issued in the event of capital increase with preemptive subscription rights maintained or waived	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
23	Delegation of authority to the Board of Directors to increase the capital, with preemptive subscription rights waived, for the benefit of individuals or legal entities, including industrial or commercial companies, or investment funds governed by French or foreign Law investing in the pharmaceutical, biotechnology or technology sector, or French or foreign investment services providers or any foreign institution with equivalent status, likely to carry out such a transaction and, as such, subscribe the securities issued	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-
24	Delegation of authority to the Board of Directors to issue common Company shares and marketable securities giving access to common shares to be issued by the Company in the event of a public exchange offer initiated by the Company, with shareholders' preemptive subscription rights waived	Adopted	5 029 351	85,28%	868 232	14,72%	-	0,00%	5 897 583	-
25	Authorization to the Board of Directors to issue common shares or marketable securities giving access to common shares to be issued, with shareholders' preemptive subscription rights waived, in consideration of contributions in kind granted to the Company and consisting of capital securities or marketable securities giving access to capital	Adopted	5 338 965	90,53%	558 618	9,47%	-	0,00%	5 897 583	-

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
26	Delegation of authority to the Board of Directors to increase the Company's share capital by capitalizing reserves, earnings or premiums	Adopted	5 431 661	92,10%	465 922	7,90%	-	0,00%	5 897 583	-
27	Delegation of authority to the Board of Directors to carry out capital increases reserved for employees enrolled in an Erytech Pharma Group savings plan, with shareholders' preemptive subscription rights waived	Rejected	2 166 796	36,74%	3 730 787	63,26%	-	0,00%	5 897 583	-
28	Authorization for the Board of Directors to award bonus shares, whether existing or to be issued, with shareholders' preemptive subscription rights waived, to corporate officers or employees of the Company or related companies	Adopted	5 029 452	85,28%	868 131	14,72%	-	0,00%	5 897 583	-
29	Authorization for the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies in the Erytech Pharma Group, entailing the waiver by shareholders of their preemptive rights to subscribe shares issued following the exercise of stock options	Adopted	5 029 452	85,28%	868 131	14,72%	-	0,00%	5 897 583	-

Resolutions (n#)	Resolutions (subject)	Results	Voting Rights							
			Voted for		Voted against		Abstention		Total	
			Voting rights	%	Voting rights	%	Voting rights	%	Voting rights	Off Vote
30	Authorization for the Board of Directors to issue detachable share subscription warrants, with shareholders' preemptive subscription rights waived, for corporate officers and employees of the Company or companies in the Erytech Pharma Group	Adopted	5 050 452	85,64%	847 131	14,36%	-	0,00%	5 897 583	-
31	Power of attorney to accomplish formalities	Adopted	5 896 423	99,98%	1 160	0,02%	-	0,00%	5 897 583	-



Translation for convenience purposes only

About ERYTECH and ERY-ASP (GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH has recently filed for European Marketing Authorization for its lead product candidate, ERY-ASP, also known under the trade name GRASPA®, following positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of ERY-ASP in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy.

ERY-ASP consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma.

Every year over 50,000 patients in Europe and the United States are diagnosed with ALL or AML. For about 80% of these patients, mainly adults and relapsing patients, current forms of L-asparaginase cannot be used due to their toxicity or as a result of allergic reactions. ERYTECH believes that the safety and efficacy profile of ERY-ASP/GRASPA®, as observed in its Phase 2/3 pivotal clinical trial, offers an attractive alternative option for the treatment of leukemia patients.

ERYTECH believes that ERY-ASP has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.

The EMA and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for ERY-ASP/GRASPA for the treatment of ALL, AML and pancreatic cancer. ERYTECH produces ERY-ASP at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for ERY-ASP for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRY).



Translation for convenience purposes only

CONTACTS

ERYTECH

Gil Beyen

Chairman and CEO

Eric Soyer

CFO and COO

+33 4 78 74 44 38

investors@erytech.com

The Ruth Group

Lee Roth

Investor relations

Kirsten Thomas

Media relations

+1 646 536 7012

lroth@theruthgroup.com

+1 508 280 6592

kthomas@theruthgroup.com

NewCap

Julien Perez

Investor relations

Nicolas Mergéau

Media relations

+33 1 44 71 98 52

erytech@newcap.eu



Ticker : ERYW

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH's website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.